Publicaciones de Interés
Datos Pantumoral
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
N Engl J Med. 2018 Feb
Datos Pantumoral
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Lancet Oncol. 2020 Apr
Datos de Carcinoma de Tiroides
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
Eur J Endocrinol. 2022 Apr
Datos de Cáncer de Pulmón
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers
JCO Precis Oncol 2022 Jan
Datos de Sarcomas
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
Cancer. 2023 Dec
Datos de Tumores Pediátricos
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Lancet Oncol. 2018 May
Datos de Tumor del SNC
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
Neuro Oncol. 2022 Jun
Datos de Cánceres de Glándulas Salivares
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
Oncologist. 2022 May
Datos de Inhibidores TRK
Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer
Am J Manag Care. 2022 Jan